Startseite Performance of afternoon (16:00 h) serum cortisol for the diagnosis of Cushing’s syndrome
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Performance of afternoon (16:00 h) serum cortisol for the diagnosis of Cushing’s syndrome

  • Hippolyte Dupuis EMAIL logo , Emilie Merlen , Julien Elices-Diez , Pierre Balayé , Christine Cortet , Arnaud Jannin , Christine Do Cao , Claire Douillard , Benoit Soulez , Nassima Ramdane , Benoit Soudan , Marie-Christine Vantyghem und Stéphanie Espiard
Veröffentlicht/Copyright: 11. Juli 2025
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 63 Heft 11

Abstract

Objectives

Late-night salivary cortisol (LNSC), which assesses the loss of the circadian rhythm of cortisol, is one of the first-line tests performed to diagnose Cushing’s syndrome (CS). Unfortunately, access to LNSC is still limited in some institutions. Alternatively, midnight serum cortisol can be measured, often combined with additional cortisol sampling over 24 h. This study investigates the performance of afternoon serum cortisol (F16h) for the positive diagnosis of hypercortisolism.

Methods

Retrospective study including consecutive patients evaluated for suspicion of CS by at least two tests among urine-free cortisol (UFC), overnight 1-mg dexamethasone suppression test (DST), and midnight serum cortisol (F00h). Patients assessed for adrenal incidentalomas or Cushing’s disease recurrence were excluded.

Results

Of the 589 included patients (41.3 % women, mean age 50.7 ± 16.3 years), 49 (8.3 %) were diagnosed with CS. F16h demonstrated significant correlations with DST, UFC, and F00h (r=0.24, p<0.001, r=0.41, p<0.001 and r=0.42, p<0.001, respectively). The optimal cut-off of the F16h was 218 nmol/L, achieving 83.7 % sensitivity, 67.4 % specificity, and a 97.8 % negative predictive value. The area under the ROC curve (AUC) for the F16h did not differ from UFC (0.83 vs. 0.79, p=0.3), yet its sensitivity was higher using the optimal diagnostic threshold. The AUC for the F16h was significantly lower than that for F00h and DST.

Conclusions

Given the limited diagnostic accuracy of both F16h and UFC, particularly in mild to moderate CS, efforts should prioritize expanding access to reliable LNSC assays for circadian rhythm assessment. Meanwhile, F16h may help rule out CS when LNSC is unavailable.

Keywords: Cushing’s syndrome; hypercortisolism; serum cortisol; urine free cortisol; dexamethasone suppression test
Corresponding author: Hippolyte Dupuis, Department of Endocrinology, Diabetology and Metabolism, Hospital Huriez, University Hospital of Lille, 59000 Lille, France, E-mail:

  1. Research ethics: Lille hospital data warehouse (INCLUDE project) has been approved by the French National Data Protection Authority (CNIL) from 2019 (authorization number: 1754053). INCLUDE data warehouse ensures that researchers at Lille University Hospital can process end-to-end data in a secure, GDPR-compliant environment.

  2. Informed consent: Not applicable.

  3. Author contributions: HD and SE wrote the manuscript. HD and SE analyzed the data. NR performed statistical analyses. EM, JED, PB, CC, AJ, CDC, CD, BS, NR, BS and MCV reviewed the manuscript and provided comments. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: The authors state no conflict of interest.

  6. Research funding: None declared.

  7. Data availability: The data that support the findings of this study are available from Lille University Hospital but restrictions apply to the availability of these data due to patient privacy regulations, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Lille University Hospital.

References

1. Nieman, LK, Biller, BMK, Findling, JW, Newell-Price, J, Savage, MO, Stewart, PM, et al.. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1526–40. https://doi.org/10.1210/jc.2008-0125.Suche in Google Scholar PubMed PubMed Central

2. Etxabe, J, Vazquez, JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol 1994;40:479–84. https://doi.org/10.1111/j.1365-2265.1994.tb02486.x.Suche in Google Scholar PubMed

3. Lindholm, J, Juul, S, Jørgensen, JO, Astrup, J, Bjerre, P, Feldt-Rasmussen, U, et al.. Incidence and late prognosis of cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 2001;86:117–23. https://doi.org/10.1210/jcem.86.1.7093.Suche in Google Scholar PubMed

4. Raff, H, Carroll, T. Cushing’s syndrome: from physiological principles to diagnosis and clinical care. J Physiol 2015;593:493–506. https://doi.org/10.1113/jphysiol.2014.282871.Suche in Google Scholar PubMed PubMed Central

5. Fenske, M. Urinary free cortisol and cortisone excretion in healthy individuals: influence of water loading. Steroids 2006;71:1014–8. https://doi.org/10.1016/j.steroids.2006.08.004.Suche in Google Scholar PubMed

6. Chan, KCA, Lit, LCW, Law, ELK, Tai, MHL, Yung, CU, Chan, MHM, et al.. Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment. Clin Chem 2004;50:757–9. https://doi.org/10.1373/clinchem.2003.029934.Suche in Google Scholar PubMed

7. Fleseriu, M, Auchus, R, Bancos, I, Ben-Shlomo, A, Bertherat, J, Biermasz, NR, et al.. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol 2021;9:847–75. https://doi.org/10.1016/s2213-8587(21)00235-7.Suche in Google Scholar

8. Guaraldi, F, La Selva, R, Samà, MT, D’Angelo, V, Gori, D, Fava, P, et al.. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J Endocrinol Investig 2018;41:549–56. https://doi.org/10.1007/s40618-017-0772-1.Suche in Google Scholar PubMed

9. Tabarin, A, Assié, G, Barat, P, Bonnet, F, Bonneville, JF, Borson-Chazot, F, et al.. Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing’s syndrome. Ann Endocrinol 2022;83:119–41. https://doi.org/10.1016/j.ando.2022.02.001.Suche in Google Scholar PubMed

10. Raff, H. Update on late-night salivary cortisol for the diagnosis of Cushing’s syndrome: methodological considerations. Endocrine 2013;44:346–9. https://doi.org/10.1007/s12020-013-0013-0.Suche in Google Scholar PubMed

11. Goyal, A, Attri, B, Gupta, Y, Kalaivani, M, Jyotsna, VP, Tandon, N. Late-night salivary cortisol cut-offs for diagnosis of Cushing syndrome using second-generation electrochemiluminescence immunoassay kits. Clin Endocrinol 2023;99:43–51. https://doi.org/10.1111/cen.14920.Suche in Google Scholar PubMed

12. Valassi, E, Franz, H, Brue, T, Feelders, RA, Netea-Maier, R, Tsagarakis, S, et al.. Diagnostic tests for Cushing’s syndrome differ from published guidelines: data from ERCUSYN. Eur J Endocrinol 2017;176:613–24. https://doi.org/10.1530/eje-16-0967.Suche in Google Scholar PubMed

13. Galm, BP, Qiao, N, Klibanski, A, Biller, BMK, Tritos, NA. Accuracy of laboratory tests for the diagnosis of cushing syndrome. J Clin Endocrinol Metab 2020;105:dgaa105. https://doi.org/10.1210/clinem/dgaa105.Suche in Google Scholar PubMed

14. DeLong, ER, DeLong, DM, Clarke-Pearson, DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45. https://doi.org/10.2307/2531595.Suche in Google Scholar

15. Kelsall, A, Newell-Price, J. Cushing’s disease-from Minnie G to key issues in the early 21st century. Lancet Diabetes Endocrinol 2019;7:959–64. https://doi.org/10.1016/s2213-8587(19)30343-2.Suche in Google Scholar PubMed

16. Boyar, RM, Witkin, M, Carruth, A, Ramsey, J. Circadian cortisol secretory rhythms in Cushing’s disease. J Clin Endocrinol Metab 1979;48:760–5. https://doi.org/10.1210/jcem-48-5-760.Suche in Google Scholar PubMed

17. Kahn, JP, Rubinow, DR, Davis, CL, Kling, M, Post, RM. Salivary cortisol: a practical method for evaluation of adrenal function. Biol Psychiatry 1988;23:335–49. https://doi.org/10.1016/0006-3223(88)90284-3.Suche in Google Scholar PubMed

18. Bolufer, P, Gandia, A, Rodriguez, A, Antonio, P. Salivary corticosteroids in the study of adrenal function. Clin Chim Acta 1989;183:217–25. https://doi.org/10.1016/0009-8981(89)90337-9.Suche in Google Scholar PubMed

19. Halbreich, U, Zumoff, B, Kream, J, Fukushima, DK. The mean 1300–1600 h plasma cortisol concentration as a diagnostic test for hypercortisolism. J Clin Endocrinol Metab 1982;54:1262–4. https://doi.org/10.1210/jcem-54-6-1262.Suche in Google Scholar PubMed

20. Putignano, P, Toja, P, Dubini, A, Pecori Giraldi, F, Corsello, SM, Cavagnini, F. Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing’s syndrome. J Clin Endocrinol Metab 2003;88:4153–7. https://doi.org/10.1210/jc.2003-030312.Suche in Google Scholar PubMed

21. Elias, PCL, Martinez, EZ, Barone, BFC, Mermejo, LM, Castro, M, Moreira, AC. Late-night salivary cortisol has a better performance than urinary free cortisol in the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 2014;99:2045–51. https://doi.org/10.1210/jc.2013-4262.Suche in Google Scholar PubMed

22. Sharma, ST, Nieman, LK, Feelders, RA. Cushing’s syndrome: epidemiology and developments in disease management. Clin Epidemiol 2015;7:281–93. https://doi.org/10.2147/clep.s44336.Suche in Google Scholar

23. Hirsch, D, Tsvetov, G, Manisterski, Y, Aviran-Barak, N, Nadler, V, Alboim, S, et al.. Incidence of Cushing’s syndrome in patients with significant hypercortisoluria. Eur J Endocrinol 2017;176:41–8. https://doi.org/10.1530/eje-16-0631.Suche in Google Scholar PubMed

24. Borsi, L, Mannelli, M, Barbieri, U, Giannotti, P, Serio, M. Measurement of urinary free cortisol by radioimmunoassay and its clinical applications. J Nucl Biol Med 1976;20:160–4.Suche in Google Scholar

25. de Pedrazzini, ME, Bruno, OD, Gros, EG. Analysis of urinary steroid profiles of women with Cushing’s syndrome by computerised gas chromatography-mass spectrometry. Acta Physiol Lat Am 1983;33:243–52.Suche in Google Scholar

26. Itsuji, Y, Tanaka, K, Tanabe, T, Takahashi, H. Evaluation of urinary excretion of free-cortisol in patients with abnormal pituitary-adrenal axes. Rinsho Byori 1997;45:265–70.Suche in Google Scholar

27. Nishikawa, T, Tamura, Y, Kumagaya, A. Studies on the determination of cortisol by Gamma Coat kit (author’s transl). Horumon Rinsho 1980;28:471–6.Suche in Google Scholar

28. Günes, M, Celik, O, Kadioglu, P. Reliability of the diagnostic tests for Cushing’s syndrome performed in a tertiary referral center. Pituitary 2013;16:139–45. https://doi.org/10.1007/s11102-012-0387-7.Suche in Google Scholar PubMed

29. Ng, CM, Lam, TK, Au Yeung, YC, Choi, CH, Iu, YP, Shek, CC, et al.. Clinical utility of late-night and post-overnight dexamethasone suppression salivary cortisone for the investigation of Cushing’s syndrome. Hong Kong Med J 2017;23:570–8. https://doi.org/10.12809/hkmj176240.Suche in Google Scholar PubMed

30. Tamada, D, Kitamura, T, Takahara, M, Tanaka, T, Takeda, M, Otsuki, M, et al.. TSH ratio as a novel diagnostic method for Cushing’s syndrome. Endocr J 2018;65:841–8. https://doi.org/10.1507/endocrj.ej18-0101.Suche in Google Scholar PubMed

31. Pecori Giraldi, F, Pivonello, R, Ambrogio, AG, De Martino, MC, De Martin, M, Scacchi, M, et al.. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing’s syndrome from pseudo-Cushing’s states. Clin Endocrinol 2007;66:251–7. https://doi.org/10.1111/j.1365-2265.2006.02717.x.Suche in Google Scholar PubMed

32. Reimondo, G, Bovio, S, Allasino, B, De Francia, S, Zaggia, B, Micossi, I, et al.. The combined low-dose dexamethasone suppression corticotropin-releasing hormone test as a tool to rule out Cushing’s syndrome. Eur J Endocrinol 2008;159:569–76. https://doi.org/10.1530/eje-08-0402.Suche in Google Scholar PubMed

33. Fassnacht, M, Tsagarakis, S, Terzolo, M, Tabarin, A, Sahdev, A, Newell-Price, J, et al.. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2023;189:G1–42. https://doi.org/10.1093/ejendo/lvad066.Suche in Google Scholar PubMed

34. Ceccato, F, Marcelli, G, Martino, M, Concettoni, C, Brugia, M, Trementino, L, et al.. The diagnostic accuracy of increased late night salivary cortisol for Cushing’s syndrome: a real-life prospective study. J Endocrinol Investig 2019;42:327–35. https://doi.org/10.1007/s40618-018-0921-1.Suche in Google Scholar PubMed

35. Ueland, GÅ, Methlie, P, Kellmann, R, Bjørgaas, M, Åsvold, BO, Thorstensen, K, et al.. Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test. Eur J Endocrinol 2017;176:705–13. https://doi.org/10.1530/eje-17-0078.Suche in Google Scholar

36. Nunes, ML, Vattaut, S, Corcuff, JB, Rault, A, Loiseau, H, Gatta, B, et al.. Late-night salivary cortisol for diagnosis of overt and subclinical Cushing’s syndrome in hospitalized and ambulatory patients. J Clin Endocrinol Metab 2009;94:456–62. https://doi.org/10.1210/jc.2008-1542.Suche in Google Scholar PubMed

37. Deutschbein, T, Unger, N, Hinrichs, J, Walz, MK, Mann, K, Petersenn, S. Late-night and low-dose dexamethasone-suppressed cortisol in saliva and serum for the diagnosis of cortisol-secreting adrenal adenomas. Eur J Endocrinol 2009;161:747–53. https://doi.org/10.1530/eje-09-0517.Suche in Google Scholar

38. Araya, AV, Romero, C, Lemp, M. Combined dexamethasone and desmopressin test in the differential diagnosis of ACTH-dependent Cushing’s syndrome and pseudo-cushing’s states. Pituitary 2017;20:602–3. https://doi.org/10.1007/s11102-017-0824-8.Suche in Google Scholar PubMed

39. Arnaldi, G, Tirabassi, G, Papa, R, Furlani, G, Trementino, L, Cardinaletti, M, et al.. Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing’s disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis. Eur J Endocrinol 2009;160:891–8. https://doi.org/10.1530/eje-09-0125.Suche in Google Scholar

40. Tirabassi, G, Faloia, E, Papa, R, Furlani, G, Boscaro, M, Arnaldi, G. Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing’s disease. J Clin Endocrinol Metab 2010;95:1115–22. https://doi.org/10.1210/jc.2009-1146.Suche in Google Scholar PubMed

41. Scaroni, C, Mondin, A, Ceccato, F. How to rule out non-neoplastic hypercortisolemia (previously known as pseudo-cushing). Pituitary 2022;25:701–4. https://doi.org/10.1007/s11102-022-01222-2.Suche in Google Scholar PubMed PubMed Central

42. Danet-Lamasou, M, Asselineau, J, Perez, P, Vivot, A, Nunes, ML, Loiseau, H, et al.. Accuracy of repeated measurements of late-night salivary cortisol to screen for early-stage recurrence of Cushing’s disease following pituitary surgery. Clin Endocrinol 2015;82:260–6. https://doi.org/10.1111/cen.12534.Suche in Google Scholar PubMed

43. Newell-Price, J, Pivonello, R, Tabarin, A, Fleseriu, M, Witek, P, Gadelha, MR, et al.. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease. Eur J Endocrinol 2020;182:207–17. https://doi.org/10.1530/eje-19-0695.Suche in Google Scholar PubMed PubMed Central

44. Raff, H, Raff, JL, Findling, JW. Late-night salivary cortisol as a screening test for Cushing’s syndrome. J Clin Endocrinol Metab 1998;83:2681–6. https://doi.org/10.1210/jcem.83.8.4936.Suche in Google Scholar PubMed

45. Carrozza, C, Corsello, SM, Paragliola, RM, Ingraudo, F, Palumbo, S, Locantore, P, et al.. Clinical accuracy of midnight salivary cortisol measured by automated electrochemiluminescence immunoassay method in Cushing’s syndrome. Ann Clin Biochem 2010;47:228–32. https://doi.org/10.1258/acb.2010.010020.Suche in Google Scholar PubMed

46. Ceccato, F, Barbot, M, Zilio, M, Frigo, AC, Albiger, N, Camozzi, V, et al.. Screening tests for Cushing’s syndrome: urinary free cortisol role measured by LC-MS/MS. J Clin Endocrinol Metab 2015;100:3856–61. https://doi.org/10.1210/jc.2015-2507.Suche in Google Scholar PubMed

47. Deutschbein, T, Broecker-Preuss, M, Hartmann, MF, Althoff, R, Wudy, SA, Mann, K, et al.. Measurement of urinary free cortisol by current immunoassays: need for sex-dependent reference ranges to define hypercortisolism. Horm Metab Res 2011;43:714–9. https://doi.org/10.1055/s-0031-1286297.Suche in Google Scholar PubMed

48. Petersenn, S, Newell-Price, J, Findling, JW, Gu, F, Maldonado, M, Sen, K, et al.. High variability in baseline urinary free cortisol values in patients with Cushing’s disease. Clin Endocrinol 2014;80:261–9. https://doi.org/10.1111/cen.12259.Suche in Google Scholar PubMed PubMed Central

49. Carrasco, CA, García, M, Goycoolea, M, Cerda, J, Bertherat, J, Padilla, O, et al.. Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing’s syndrome using an automated immunoassay system. Endocrine 2012;41:487–93. https://doi.org/10.1007/s12020-012-9597-z.Suche in Google Scholar PubMed

50. Pecori Giraldi, F, Ambrogio, AG. Variability in laboratory parameters used for management of Cushing’s syndrome. Endocrine 2015;50:580–9. https://doi.org/10.1007/s12020-015-0676-9.Suche in Google Scholar PubMed PubMed Central

51. Pikkarainen, L, Alfthan, H, Markkanen, H, Sane, T. Midnight serum cortisol: comparison of healthy volunteers and hospitalized patients with Cushing’s syndrome. Scand J Clin Lab Invest 2002;62:357–60.Suche in Google Scholar

52. Maes, M, Mommen, K, Hendrickx, D, Peeters, D, D’Hondt, P, Ranjan, R, et al.. Components of biological variation, including seasonality, in blood concentrations of TSH, TT3, FT4, PRL, cortisol and testosterone in healthy volunteers. Clin Endocrinol 1997;46:587–98. https://doi.org/10.1046/j.1365-2265.1997.1881002.x.Suche in Google Scholar PubMed

Supplementary Material

This article contains supplementary material (https://doi.org/10.1515/cclm-2025-0133).

Received: 2025-02-05
Accepted: 2025-07-03
Published Online: 2025-07-11
Published in Print: 2025-10-27

© 2025 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Advancing diagnostic stewardship through claims-based utilization analysis: toward a system-wide vision of diagnostic excellence
  4. Review
  5. Biomarkers in body fluids and their detection techniques for human intestinal permeability assessment
  6. Mini Review
  7. Challenges of using natriuretic peptides to screen for the risk of developing heart failure in patients with diabetes: a report from the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Clinical Applications of Cardiac Bio-Markers (C-CB)
  8. Opinion Papers
  9. Reference intervals in value-based laboratory medicine: a shift from single-point measurements to metabolic variation-based models
  10. Overview of laboratory diagnostics for immediate management of patients presenting to the emergency department with acute bleeding
  11. What Matters Most: an Age-Friendly approach to pathology and laboratory medicine
  12. No fault or negligence after an adverse analytical finding due to a contaminated supplement: mission impossible. Two examples involving trimetazidine
  13. General Clinical Chemistry and Laboratory Medicine
  14. Utilization analysis of laboratory tests using health insurance claims data: advancing nationwide diagnostic stewardship monitoring systems
  15. Evaluating large language models as clinical laboratory test recommenders in primary and emergency care: a crucial step in clinical decision making
  16. A novel corrective model based on red blood cells indices and haemolysis index enables accurate unhaemolysed potassium determination in haemolysed samples – Hemokalc project
  17. Validation of (self-collected) capillary blood using a topper collection system as alternative for venous sampling for 15 common clinical chemistry analytes
  18. Acoustophoresis-based blood sampling and plasma separation for potentially minimizing sampling-related blood loss
  19. Clinical validation of a liquid chromatography single quadrupole mass spectrometry (LC-MS) method using Waters Kairos™ Amino Acid Kit reagents
  20. Robustness of steroidomics-based machine learning for diagnosis of primary aldosteronism: a laboratory medicine perspective
  21. Investigation of the possible cause of over-estimation of human aldosterone in plasma, using a unique, non-synthetic human aldosterone-free matrix
  22. Performance of afternoon (16:00 h) serum cortisol for the diagnosis of Cushing’s syndrome
  23. MAGLUMI® Tacrolimus (CLIA) assay: analytical performances and comparison with LC-MS/MS and ARCHITECT Tacrolimus (CMIA) assay
  24. Assessment of 2023 ACR/EULAR antiphospholipid syndrome classification criteria in a Spanish cohort
  25. Comprehensive evaluation of antiphospholipid antibody testing methodologies in APS diagnosis: performance comparisons across assay systems and clinical subtypes
  26. Candidate Reference Measurement Procedures and Materials
  27. Exploring commutable materials for serum folate measurement: challenges in cross-method harmonization
  28. Reference Values and Biological Variations
  29. Reference ranges for ionized calcium in plasma in Danish children aged 0 days to 3 years using laboratory registry data
  30. A step forward in pediatric hemophagocytic lymphohistiocytosis and autoimmune disease: pediatric reference interval for serum soluble IL-2 receptor and soluble CD163
  31. Cancer Diagnostics
  32. Cellular expression of PD-1, PD-L1 and CTLA-4 in patients with JAK2V617F mutated myeloproliferative disorders
  33. Diabetes
  34. Serum N-glycans as independent predictors of the incidence of type 2 diabetes: a prospective investigation in the AEGIS cohort
  35. Infectious Diseases
  36. An assessment of molecular diagnosis of tuberculosis and multi-drug resistant tuberculosis testing and quality assessment: findings of an international survey
  37. Letters to the Editor
  38. Targeting low-value laboratory care
  39. Is time a significant factor in the release of potassium from lithium heparin plasma and serum?
  40. External quality assessment in resource-constrained laboratories: a survey of practices and perceptions in Nepal
  41. Is successfulness of platelet clump disaggregation by vortexing influenced by platelet measurement methods?
  42. Oligoclonal banding analysis: assessing plasma use and time interval requirements for paired CSF and blood
https://doi.org/10.1515/cclm-2025-0133
Schlagwörter für diesen Artikel
Cushing’s syndrome; hypercortisolism; serum cortisol; urine free cortisol; dexamethasone suppression test

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Advancing diagnostic stewardship through claims-based utilization analysis: toward a system-wide vision of diagnostic excellence
  4. Review
  5. Biomarkers in body fluids and their detection techniques for human intestinal permeability assessment
  6. Mini Review
  7. Challenges of using natriuretic peptides to screen for the risk of developing heart failure in patients with diabetes: a report from the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Clinical Applications of Cardiac Bio-Markers (C-CB)
  8. Opinion Papers
  9. Reference intervals in value-based laboratory medicine: a shift from single-point measurements to metabolic variation-based models
  10. Overview of laboratory diagnostics for immediate management of patients presenting to the emergency department with acute bleeding
  11. What Matters Most: an Age-Friendly approach to pathology and laboratory medicine
  12. No fault or negligence after an adverse analytical finding due to a contaminated supplement: mission impossible. Two examples involving trimetazidine
  13. General Clinical Chemistry and Laboratory Medicine
  14. Utilization analysis of laboratory tests using health insurance claims data: advancing nationwide diagnostic stewardship monitoring systems
  15. Evaluating large language models as clinical laboratory test recommenders in primary and emergency care: a crucial step in clinical decision making
  16. A novel corrective model based on red blood cells indices and haemolysis index enables accurate unhaemolysed potassium determination in haemolysed samples – Hemokalc project
  17. Validation of (self-collected) capillary blood using a topper collection system as alternative for venous sampling for 15 common clinical chemistry analytes
  18. Acoustophoresis-based blood sampling and plasma separation for potentially minimizing sampling-related blood loss
  19. Clinical validation of a liquid chromatography single quadrupole mass spectrometry (LC-MS) method using Waters Kairos™ Amino Acid Kit reagents
  20. Robustness of steroidomics-based machine learning for diagnosis of primary aldosteronism: a laboratory medicine perspective
  21. Investigation of the possible cause of over-estimation of human aldosterone in plasma, using a unique, non-synthetic human aldosterone-free matrix
  22. Performance of afternoon (16:00 h) serum cortisol for the diagnosis of Cushing’s syndrome
  23. MAGLUMI® Tacrolimus (CLIA) assay: analytical performances and comparison with LC-MS/MS and ARCHITECT Tacrolimus (CMIA) assay
  24. Assessment of 2023 ACR/EULAR antiphospholipid syndrome classification criteria in a Spanish cohort
  25. Comprehensive evaluation of antiphospholipid antibody testing methodologies in APS diagnosis: performance comparisons across assay systems and clinical subtypes
  26. Candidate Reference Measurement Procedures and Materials
  27. Exploring commutable materials for serum folate measurement: challenges in cross-method harmonization
  28. Reference Values and Biological Variations
  29. Reference ranges for ionized calcium in plasma in Danish children aged 0 days to 3 years using laboratory registry data
  30. A step forward in pediatric hemophagocytic lymphohistiocytosis and autoimmune disease: pediatric reference interval for serum soluble IL-2 receptor and soluble CD163
  31. Cancer Diagnostics
  32. Cellular expression of PD-1, PD-L1 and CTLA-4 in patients with JAK2V617F mutated myeloproliferative disorders
  33. Diabetes
  34. Serum N-glycans as independent predictors of the incidence of type 2 diabetes: a prospective investigation in the AEGIS cohort
  35. Infectious Diseases
  36. An assessment of molecular diagnosis of tuberculosis and multi-drug resistant tuberculosis testing and quality assessment: findings of an international survey
  37. Letters to the Editor
  38. Targeting low-value laboratory care
  39. Is time a significant factor in the release of potassium from lithium heparin plasma and serum?
  40. External quality assessment in resource-constrained laboratories: a survey of practices and perceptions in Nepal
  41. Is successfulness of platelet clump disaggregation by vortexing influenced by platelet measurement methods?
  42. Oligoclonal banding analysis: assessing plasma use and time interval requirements for paired CSF and blood
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 1.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2025-0133/html?lang=de
Button zum nach oben scrollen